EpiEndo has been nominated for the Nordic Life Science Business Class and Delegates Choice Awards
EpiEndo is among 9 BioTechs that are nominated for the NLS “Business Class Award”. The selected companies must “show scientific excellence and run projects that have a break-through possibility or have already made it to the market adding significant value to patients”.
For the“Delegates Choice Award”: the audience will be asked to vote for the company they are most likely to invest in should they be given the opportunity.
The winner will be announced at the NLSDays in Malmö on the 10th of September.
The nominated companies are:
Akthelia (Iceland) A novel antimicrobial platform
Cirqle (Denmark) Focused on developing innovative contraceptives
Delsitech (Finland) New nanotech solutions in drug delivery
Elypta (Sweden) Metabolic biomarkers and AI to detect cancer
EpiEndo (Iceland) Focused on novel solutions for chronic airway diseases
Saromics (Sweden) Protein crystallography and drug discovery services
Synklino (Denmark) Eradicating cytomegalovirus infections
Vaccibody (Norway)Tailored vaccine therapy
Kongsberg Beam Technology (Norway) Precision against cancer